ATE332364T1 - Verfahren zur gewinnung von purifizierter virenzuammensetzung - Google Patents

Verfahren zur gewinnung von purifizierter virenzuammensetzung

Info

Publication number
ATE332364T1
ATE332364T1 AT00906444T AT00906444T ATE332364T1 AT E332364 T1 ATE332364 T1 AT E332364T1 AT 00906444 T AT00906444 T AT 00906444T AT 00906444 T AT00906444 T AT 00906444T AT E332364 T1 ATE332364 T1 AT E332364T1
Authority
AT
Austria
Prior art keywords
purified virus
virus composition
obtaining purified
viral
particles
Prior art date
Application number
AT00906444T
Other languages
English (en)
Inventor
Michel Koehl
David Gaillac
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Application granted granted Critical
Publication of ATE332364T1 publication Critical patent/ATE332364T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10051—Methods of production or purification of viral material

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT00906444T 1999-02-22 2000-02-21 Verfahren zur gewinnung von purifizierter virenzuammensetzung ATE332364T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9902167 1999-02-22

Publications (1)

Publication Number Publication Date
ATE332364T1 true ATE332364T1 (de) 2006-07-15

Family

ID=9542357

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00906444T ATE332364T1 (de) 1999-02-22 2000-02-21 Verfahren zur gewinnung von purifizierter virenzuammensetzung

Country Status (8)

Country Link
US (1) US7264958B1 (de)
EP (1) EP1155120B1 (de)
JP (2) JP4802366B2 (de)
AT (1) ATE332364T1 (de)
AU (1) AU774437B2 (de)
CA (1) CA2364934C (de)
DE (1) DE60029195T2 (de)
WO (1) WO2000050573A1 (de)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE200000605A (et) 1998-04-22 2002-04-15 Genvec, Inc. Adenoviiruse efektiivne puhastamine
EP1407006B9 (de) * 2001-12-20 2006-10-18 Bavarian Nordic A/S Methode zur gewinnung und reinigung von poxviren aus infizierten zellen
ATE500267T1 (de) 2003-07-21 2011-03-15 Transgene Sa Multifunktionelle cytokine
CN1922308A (zh) 2004-02-23 2007-02-28 克鲁塞尔荷兰公司 病毒纯化方法
CA2602944C (en) 2005-04-11 2015-08-11 Crucell Holland B.V. Virus purification using ultrafiltration
JP4670583B2 (ja) * 2005-10-20 2011-04-13 チッソ株式会社 水溶性カチオン性磁気微粒子を用いた脂質ベシクルの分離又は検出方法
SG188908A1 (en) 2006-07-14 2013-04-30 Wisconsin Alumni Res Found Adsorptive membranes for trapping viruses
US8420103B2 (en) 2007-01-30 2013-04-16 Transgene S.A. Papillomavirus vaccines
WO2010060719A1 (en) 2008-11-03 2010-06-03 Crucell Holland B.V. Method for the production of adenoviral vectors
DK2382474T3 (en) 2009-01-20 2015-04-07 Transgene Sa SOLUBLE ICAM-1 as a biomarker FOR PREDICTION OF THERAPEUTIC RESPONSE
MX2011010061A (es) 2009-03-24 2011-11-18 Transgene Sa Biomarcador para monitorear pacientes.
EP2419728B1 (de) 2009-04-17 2014-01-08 Transgene SA Biomarker für patientenüberwachung
AU2010270313B2 (en) 2009-07-10 2014-05-22 Transgene Sa Biomarker for selecting patients and related methods
KR20120052352A (ko) 2009-08-07 2012-05-23 트랜스진 에스.에이. Ｈｂｖ 감염을 치료하는 조성물
EP2536829B1 (de) 2010-02-15 2016-04-06 Crucell Holland B.V. Verfahren zur Herstellung von adenoviralen Ad26-Vektoren
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
SG190031A1 (en) * 2010-10-27 2013-06-28 Philip Morris Prod Methods for capturing virus like particles from plants using expanded bed chromatography
BR112013014457A8 (pt) 2010-12-09 2017-12-19 Pasteur Institut usos da enzima 6-metilguanina-dna-metiltrasferase (mgmt, ec 2.1.1.63) para aumentar a produção de proteína heteróloga, bem como vetor de expressão, células recombinantes e polipeptídeo de fusão compreendendo sinal de secreção peptídica e proteína snap
ES2655051T3 (es) 2011-08-26 2018-02-16 Wisconsin Alumni Research Foundation Virus de la gripe con segmento génico PB2 mutante como vacunas vivas atenuadas
TW201321016A (zh) 2011-09-29 2013-06-01 Transgene Sa 免疫療法組成物及用於治療ｃ型肝炎病毒感染之療程（二）
TW201318637A (zh) 2011-09-29 2013-05-16 Transgene Sa 免疫療法組成物及用於治療ｃ型肝炎病毒感染之療程（一）
WO2014009433A1 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterium resuscitation promoting factor for use as adjuvant
CA2878800A1 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterial antigen vaccine
WO2014066443A1 (en) 2012-10-23 2014-05-01 Emory University Gm-csf and il-4 conjugates, compositions, and methods related thereto
JP6797680B2 (ja) 2013-06-14 2020-12-16 サイオクサス セラピューティクス リミテッド Ｂ型アデノウイルスのための投与計画および製剤
SI3021859T1 (en) 2013-10-25 2018-04-30 Psioxus Therapeutics Limited Oncolytic adenoviruses equipped with heterologous genes
RU2695462C2 (ru) 2014-01-09 2019-07-23 Трансген Са Гибридизация гетероолигомерных микобактериальных антигенов
US10053671B2 (en) 2014-06-20 2018-08-21 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
EP3256156B1 (de) 2015-02-13 2025-02-12 Transgene Immunotherapeutischer impfstoff und antikörperkombinationstherapie
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
CN108697745A (zh) 2015-12-17 2018-10-23 皮斯奥克斯治疗公司 编码抗tcr复合体抗体或片段的b组腺病毒
AU2017221444B2 (en) 2016-02-19 2021-07-29 Wisconsin Alumni Research Foundation (Warf) Improved influenza B virus replication for vaccine development
CA3023022A1 (en) 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
IL303187A (en) 2016-08-29 2023-07-01 Akamis Bio Ltd Adenovirus with bispecific T cell activator
EP3522920A2 (de) 2016-10-10 2019-08-14 Transgene SA Immuntherapeutisches produkt und mdsc-modulator-kombinationstherapie
JP7078620B2 (ja) 2016-11-16 2022-05-31 イミュノミック セラピューティックス， インコーポレイテッド アレルギーの治療のための核酸
EP4512477A3 (de) 2017-04-22 2025-06-11 Immunomic Therapeutics, Inc. Verbesserte lampenkonstruktionen
CN110913892A (zh) 2017-05-02 2020-03-24 免疫治疗有限公司 包含癌抗原的lamp(溶酶体相关膜蛋白)构建物
US11197926B2 (en) 2017-10-25 2021-12-14 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized HA for replication in eggs
GB201801614D0 (en) 2018-01-31 2018-03-14 Psioxus Therapeutics Ltd Formulation
CA3100004A1 (en) 2018-05-15 2019-11-21 Immunomic Therapeutics, Inc. Improved lamp constructs comprising allergens
US12343390B2 (en) 2018-08-07 2025-07-01 Wisconsin Alumni Research Foundation (Warf) Recombinant biologically contained filovirus vaccine
US11389523B2 (en) 2018-08-20 2022-07-19 Wisconsin Alumni Research Foundation (Warf) Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (HA) protein
CA3113648A1 (en) 2018-09-21 2020-03-26 University Of Connecticut Compositions and methods to restore paternal ube3a gene expression in human angelman syndrome
CN113543875A (zh) * 2018-11-22 2021-10-22 固定噬菌体有限公司 产生固定噬菌体
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
CN113874496A (zh) 2019-02-08 2021-12-31 威斯康星校友研究基金会(Warf) 人源化细胞系
WO2020223699A1 (en) 2019-05-01 2020-11-05 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
GB201909081D0 (en) * 2019-06-25 2019-08-07 Psioxus Therapeutics Ltd Method
JP7627911B2 (ja) 2019-08-27 2025-02-07 ウィスコンシン アルムニ リサーチ ファンデイション 卵内複製のための安定化されたｈａを持つ組換えインフルエンザウイルス
WO2021077051A1 (en) 2019-10-18 2021-04-22 Immunomic Therapeutics, Inc Improved lamp constructs comprising cancer antigens
AU2020385683A1 (en) 2019-11-18 2022-06-30 Janssen Biotech, Inc. Vaccines based on mutant CALR and JAK2 and their uses
WO2021150874A1 (en) 2020-01-24 2021-07-29 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized na
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
TW202144389A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在多發性骨髓瘤中表現之新抗原及其用途
WO2021195410A1 (en) 2020-03-25 2021-09-30 Wisconsin Alumni Research Foundation (Warf) Recombinant multivalent influenza viruses
JP2023521194A (ja) 2020-04-13 2023-05-23 ヤンセン バイオテツク，インコーポレーテツド Ｐｓｍａ及びｓｔｅａｐ１ワクチン並びにそれらの使用
US20230024133A1 (en) 2020-07-06 2023-01-26 Janssen Biotech, Inc. Prostate Neoantigens And Their Uses
WO2022009051A1 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. A method for determining responsiveness to prostate cancer treatment
WO2022009052A2 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
US20230241530A1 (en) * 2022-02-01 2023-08-03 W. L. Gore & Associates, Inc. Affinity chromatography devices containing a heat treated fibrillated polymer membrane for the separation of mrna and viral vectors from an aqueous mixture
EP4508071A1 (de) 2022-04-10 2025-02-19 Immunomic Therapeutics, Inc. Bicistronische lampenkonstrukte mit immunreaktionserhöhenden genen und verfahren zur verwendung davon
WO2025158316A1 (en) 2024-01-26 2025-07-31 Janssen Biotech, Inc. Ovarian neoantigens and use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0328256A1 (de) * 1988-01-21 1989-08-16 Owens-Corning Fiberglas Corporation Glasfaser, überzogen mit Agarose, zur Verwendung als Säulenpackung oder chromatographisches Medium in Biotrennungen
GB8806605D0 (en) * 1988-03-19 1988-04-20 Robinson E Composite adsorbents
SE9101149D0 (sv) 1991-04-17 1991-04-17 Pharmacia Lkb Biotech Beads for down stream processing
DE4128953A1 (de) * 1991-08-30 1993-03-04 Basf Ag Verfahren zur kultivierung von saeugerzellen im fliessbettreaktor
US5837520A (en) * 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
FR2737730B1 (fr) 1995-08-10 1997-09-05 Pasteur Merieux Serums Vacc Procede de purification de virus par chromatographie
AU722196B2 (en) * 1995-08-30 2000-07-27 Genzyme Corporation Chromatographic purification of adenovirus and AAV
US6027888A (en) * 1996-04-05 2000-02-22 Board Of Regents, The University Of Texas System Methods for producing soluble, biologically-active disulfide-bond containing eukaryotic proteins in bacterial cells
CZ438398A3 (cs) 1996-07-01 1999-03-17 Rhone-Poulenc Rorer S. A. Způsob přípravy rekombinantních adenovirů
JP4492826B2 (ja) 1996-11-20 2010-06-30 イントロジェン セラピューティクス，インコーポレイテッド アデノウイルスベクターの産生および精製のための改良された方法
DE69739961D1 (de) 1996-12-13 2010-09-23 Schering Corp Methoden zur Virus-Reinigung
SE9700383D0 (sv) * 1997-02-04 1997-02-04 Pharmacia Biotech Ab An adsorption/separation method and a medium for adsorption/separation
JP2001519930A (ja) 1998-02-04 2001-10-23 サンマイクロシステムズ インコーポレーテッド 階層型ハッシュを用いた効率的な認証及び完全性検査の方法及びその装置
EE200000605A (et) 1998-04-22 2002-04-15 Genvec, Inc. Adenoviiruse efektiivne puhastamine

Also Published As

Publication number Publication date
EP1155120A1 (de) 2001-11-21
CA2364934C (fr) 2011-10-18
JP2002536992A (ja) 2002-11-05
EP1155120B1 (de) 2006-07-05
US7264958B1 (en) 2007-09-04
AU2811800A (en) 2000-09-14
AU774437B2 (en) 2004-06-24
JP2011120596A (ja) 2011-06-23
JP4802366B2 (ja) 2011-10-26
DE60029195D1 (de) 2006-08-17
DE60029195T2 (de) 2007-06-28
WO2000050573A1 (fr) 2000-08-31
CA2364934A1 (fr) 2000-08-31

Similar Documents

Publication Publication Date Title
DE60029195D1 (de) Verfahren zur gewinnung von purifizierter virenzuammensetzung
DE69931053D1 (de) Verfahren zur reinigung von menschlichen, dem papillomavirus ähnlichen partikeln.
ATE306252T1 (de) Verfahren zur herstellung kristalliner partikel zur inhalation
ATE278785T1 (de) Neues verfahren zur gewinnung und reinigung von fusionsproteinen
ATE322252T1 (de) Verfahren zur herstellung und sammlung von kristallinen partikeln
DE60114348D1 (de) Verfahren zur Reinigung von Gasen
DE69637509D1 (de) Verfahren zur reinigung von faktor-ix
DE69908998D1 (de) Verfahren zur Herstellung von Kohlenstoff
DE69703957D1 (de) Verfahren zur Herstellung von kristallinen Ceroxidteilchen.
DE59800264D1 (de) Verfahren zur Herstellung von SiO2-Granulat
DE60132094D1 (de) Verfahren zur Herstellung von gereinigten Partikeln
DE60120819D1 (de) Verfahren zur adsorptiven Trennung von Kohlendioxid
DE60330146D1 (de) Verfahren zur reinigung von fibrinogen
DE60203975D1 (de) Verfahren zur Herstellung von magnetischen Teilchen, magnetische Teilchen und magnetischer Werkstoff
DE69531308D1 (de) Verfahren zur Herstellung von gereinigten papillomavirus Proteinen
DE60011396D1 (de) Verfahren zur herstellung von iopamidol
AU2003279240A1 (en) Methods for purifying viral particles for gene therapy
ATE509889T1 (de) Verfahren zur herstellung von granulatförmigem umhüllten natriumpercarbonat und verfahrensgemäss erhältliches produkt
DE60105209D1 (de) Verfahren zur Herstellung von niedrig substituierter Hydroxypropylcellulose-Partikeln
DE69931976D1 (de) Verfahren zur Herstellung von Aminophosphinen und Aminophosphinoxiden, Zwischenprodukte dafür
DE60032077D1 (de) Verfahren zur dehalogenierung von kohlenwasserstoffhaltigen kohlenstoff-kohlenstoff doppelbindungen
DE60129907D1 (de) Verfahren zur Reinigung von Isophthalonitril
DE69300901D1 (de) Verfahren zur Reinigung von 1,1,1,2-Tetrafluorethan.
DE60002020D1 (de) Verfahren zur Herstellen von hochreinem Xylitol
AU2003265052A1 (en) Process for the purification of recombinant proteins from complex media and purified proteins obtained thereby

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1155120

Country of ref document: EP